市場調査レポート
商品コード
1379093
吸入麻酔市場:世界の産業動向、シェア、規模、成長、機会、2023-2028年予測Inhalation Anesthesia Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028 |
● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。 詳細はお問い合わせください。
吸入麻酔市場:世界の産業動向、シェア、規模、成長、機会、2023-2028年予測 |
出版日: 2023年11月02日
発行: IMARC
ページ情報: 英文 142 Pages
納期: 2~3営業日
|
世界の吸入麻酔市場規模は2022年に16億米ドルに達しました。今後、IMARC Groupは、2028年には19億米ドルに達し、2022~2028年の成長率(CAGR)は2.9%になると予測しています。慢性疾患の有病率の増加、製薬会社、医療機器メーカー、ヘルスケア機関の連携、政府および民間ヘルスケアプロバイダーによる最先端機器への投資の増加は、市場を推進している主な要因の一部です。
吸入麻酔は、さまざまな外科手術を受ける患者に、可逆的な意識喪失状態と痛みに対する鈍感さを誘発するために採用される医療技術です。この方法では、患者の気道に装着した呼吸マスクや気管内チューブを通して、ガスや蒸気の形で麻酔薬を投与します。亜酸化窒素、セボフルラン、イソフルラン、デスフルランなどの麻酔薬は、重要な身体機能を維持しながら、望ましいレベルの鎮静と鎮痛が得られるよう、慎重にバランスが調整されています。吸入された麻酔薬は患者の呼吸器系を通り、肺に達し、血流に入り、最終的には脳と中枢神経系に影響を及ぼします。
外科的治療を必要とする慢性疾患の有病率の増加が、世界市場を牽引しています。しかし、新興経済諸国が発展し、個人がヘルスケア・サービスを利用しやすくなるにつれ、ヘルスケア支出は増加する傾向にあります。これには、麻酔機器を含む医療機器や技術への投資も含まれます。政府や民間ヘルスケアプロバイダーは、患者のケアと安全性を向上させるため、最先端の機器への投資に積極的です。しかし、患者の安全や麻酔の実施に関する規制やガイドラインは、使用する麻酔薬や機器の種類に影響を与える可能性があります。市場の成長は、こうした規制の遵守と一致することが多く、新しい技術や薬剤の採用につながる可能性があります。また、製薬企業、医療機器メーカー、ヘルスケア機関の連携は、新しい麻酔技術の開発と普及につながり、市場拡大を後押しします。さらに、吸入麻酔を安全かつ効果的に実施するためには、熟練した麻酔専門家の確保が不可欠です。研修プログラムや有能な麻酔スタッフを維持するための努力は、これらの技術の需要に影響を与える可能性があります。
麻酔薬とデリバリーシステムの絶え間ない進歩
製薬会社や医療機器メーカーは、より効果的で安全な麻酔ガスや蒸気を開発するため、研究開発に多額の投資を行っています。これらの技術革新は、副作用のリスクを低減し、麻酔体験全体を改善することで、患者の転帰を向上させることを目的としています。薬物動態プロファイルが改善された新しい薬剤が開発されており、麻酔の導入と麻酔からの覚醒をより迅速に行えるため、患者が手術室で過ごす時間が短縮されます。さらに、精密な気化器やモニタリング技術を含む高度な送達システムの開発により、麻酔薬の正確な投与と漸増が保証され、投与量の過不足の可能性が最小限に抑えられています。このような進歩は、患者ケアの向上に貢献するだけでなく、ヘルスケアプロバイダーがこのような最新のソリューションを採用するようになるため、吸入麻酔市場の成長に拍車をかけています。
外科手術と患者数の増加
人口の増加は、高齢化社会を伴うことが多く、外科手術の需要の高まりに直結します。高齢者人口は、心血管疾患、人工関節置換術、がん治療など、加齢に関連した病気のために、より多くの医療介入を必要とする傾向があります。その結果、整形外科、心臓病学、腫瘍学、一般外科などの外科専門分野の需要が増加しています。吸入麻酔は、その迅速な麻酔開始と制御可能な鎮静の深さにより、これらの処置に好ましい選択肢であることが証明されています。吸入麻酔は、患者の無意識の確保と生理的安定性の維持のバランスを提供します。さらに、医学的知識と技術の進歩は、実現可能な外科的介入の範囲を広げました。低侵襲手術、ロボット支援手術、その他の革新的な技術が登場し、より安全で迅速な介入が可能になっています。
外来手術センターの拡大
ASCは、費用対効果、患者滞在期間の短縮、院内感染リスクの低減など、数多くの利点を提供します。吸入麻酔は、その迅速な麻酔開始と迅速な回復プロファイルのため、ASCの要件によく合致しています。ASCで手術を受ける患者は、日常生活により早く戻れる吸入麻酔を好むことが多いです。さらに、術後の吐き気や嘔吐を最小限に抑える吸入麻酔の能力は、外来では特に価値があります。外来手術の需要増に対応するためにASCの数が増えるにつれて、吸入麻酔の需要は大幅な増加が見込まれます。この動向はまた、ASCのユニークなニーズに合わせた、よりポータブルでユーザーフレンドリーな麻酔デリバリーシステムの開発をメーカーに促しています。
The global inhalation anesthesia market size reached US$ 1.6 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 1.9 Billion by 2028, exhibiting a growth rate (CAGR) of 2.9% during 2022-2028. The increasing prevalence of chronic medical disorders, collaborations between pharmaceutical companies, medical device manufacturers, and healthcare institutions, and the rising investments by governments and private healthcare providers in state-of-the-art equipment are some of the major factors propelling the market.
Inhalation anesthesia is a medical technique employed to induce a reversible state of unconsciousness and insensitivity to pain in patients undergoing various surgical procedures. This method involves administering anesthetic agents in the form of gases or vapors through a breathing mask or an endotracheal tube placed in the patient's airway. These anesthetic agents, such as nitrous oxide, sevoflurane, isoflurane, and desflurane, are carefully balanced to achieve the desired level of sedation and pain relief while maintaining vital bodily functions. The inhaled anesthetics travel through the patient's respiratory system, reaching the lungs and then entering the bloodstream, eventually affecting the brain and central nervous system.
The increasing prevalence of chronic medical disorders requiring surgical treatments is driving the global market. Moroever, as economies develop and individuals have better access to healthcare services, healthcare expenditure tends to increase. This includes investments in medical equipment and technologies, including anesthesia equipment. Governments and private healthcare providers are willing to invest in state-of-the-art equipment to improve patient care and safety. Moroever, regulations, and guidelines related to patient safety and anesthesia practices can impact the types of anesthesia agents and equipment used. Market growth is often aligned with compliance with these regulations, which can lead to the adoption of newer technologies and agents. Also, collaborations between pharmaceutical companies, medical device manufacturers, and healthcare institutions can lead to the development and promotion of new anesthesia technologies, impelling market expansion. Furthermore, the availability of skilled anesthesia professionals is crucial for administering inhalation anesthesia safely and effectively. Training programs and efforts to maintain a competent anesthesia workforce can impact the demand for these techniques.
Continual Advancements in Anesthetic Agents and Delivery Systems
Pharmaceutical companies and medical device manufacturers are heavily investing in research and development to create more effective and safer anesthetic gases and vapors. These innovations aim to enhance patient outcomes by reducing the risk of adverse effects and improving the overall anesthesia experience. Newer agents are being developed with improved pharmacokinetic profiles, enabling faster induction and emergence from anesthesia, thus shortening the time patients spend in the operating room. Furthermore, the development of sophisticated delivery systems, including precise vaporizers and monitoring technologies, ensures accurate administration and titration of anesthetic agents, minimizing the chances of over or under dosing. These advancements not only contribute to better patient care but also attract healthcare providers to adopt these modern solutions, thus catalyzing the growth of the inhalation anesthesia market.
Rising Surgical Procedures and Patient Volume
Population growth, often accompanied by an aging demographic, directly correlates with a heightened demand for surgical procedures. The elderly population tends to require more medical interventions due to age-related ailments, such as cardiovascular diseases, joint replacements, and cancer treatments. Consequently, surgical specialties such as orthopedics, cardiology, oncology, and general surgery have seen a rise in demand. Inhalation anesthesia proves to be a preferred option for these procedures due to its rapid onset and controllable depth of sedation. It offers a balance between ensuring patient's unconsciousness and maintaining their physiological stability. Furthermore, the expansion of medical knowledge and technology has broadened the spectrum of feasible surgical interventions. Minimally invasive procedures, robotics-assisted surgeries, and other innovative techniques have emerged, allowing for safer and quicker interventions.
Expansion of Ambulatory Surgical Centers
ASCs offer numerous advantages, such as cost-effectiveness, shorter patient stays, and reduced risk of hospital-acquired infections. Inhalation anesthesia aligns well with the requirements of ASCs due to its rapid onset and quick recovery profile. Patients undergoing procedures at ASCs often prefer inhalation anesthesia as it allows them to return to their daily activities more swiftly. Moreover, inhalation anesthesia's ability to minimize post-operative nausea and vomiting is particularly valuable in an outpatient setting. As the number of ASCs grows to accommodate the increasing demand for outpatient surgeries, the demand for inhalation anesthesia is expected to witness a significant rise. This trend also encourages manufacturers to develop more portable and user-friendly anesthesia delivery systems tailored to the unique needs of ASCs.
IMARC Group provides an analysis of the key trends in each segment of the global inhalation anesthesia market report, along with forecasts at the global, regional and country levels from 2023-2028. Our report has categorized the market based on product, application and end user.
Desflurane
Sevoflurane
Isoflurane
Others
Sevoflurane dominates the market
The report has provided a detailed breakup and analysis of the market based on the product. This includes desflurane, sevoflurane, isoflurane, and others. According to the report, sevoflurane represented the largest segment.
Sevoflurane's popularity is largely due to its favorable pharmacokinetic profile. With its rapid induction and emergence characteristics, sevoflurane enables anesthesiologists to guide patients swiftly and smoothly into and out of anesthesia. This not only enhances operational efficiency in medical settings but also ensures that patients experience minimal delay in the start and conclusion of surgical procedures. Moreover, sevoflurane's low blood-gas solubility allows for rapid equilibration between the lungs and the bloodstream, translating into quicker adjustments in the depth of anesthesia and the potential for faster recoveries. Sevoflurane's reduced likelihood of causing organ toxicity or compromising vital functions offers a degree of reassurance to both medical professionals and patients. This safety aspect has been pivotal in cementing sevoflurane's role as a cornerstone of inhalation anesthesia practice, particularly in paediatric and geriatric populations where safety is of paramount concern.
Induction
Maintenance
Maintenance dominates the market
The report has provided a detailed breakup and analysis of the market based on the application. This includes induction and maintenance. According to the report, maintenance represented the largest segment.
The prominence of the maintenance phase is attributed to its role in ensuring patient comfort, surgical precision, and optimal outcomes. Once the patient is induced into anesthesia and the initial surgical incisions are made, maintaining the appropriate anesthetic depth becomes paramount. Anesthesia providers carefully titrate inhalation anesthetic agents to balance the patient's need for complete insensitivity to pain while avoiding over-sedation, which could lead to complications or lengthened recovery times. This dynamic balance requires continuous monitoring and adjustment throughout the procedure, highlighting the importance of skilled anesthesiologists. Moreover, the maintenance phase is directly linked to surgical efficacy and precision. Surgeons rely on patients being adequately anesthetized and immobilized to perform delicate procedures with accuracy. Any fluctuation in the anesthesia depth during the maintenance phase could lead to patient movement or awareness, potentially compromising the surgery's success.
Hospitals
Ambulatory Surgical Centers
Others
Hospitals dominate the market
The report has provided a detailed breakup and analysis of the market based on the end user. This includes hospitals, ambulatory surgical centers, and others. According to the report, hospitals represented the largest segment.
Hospitals offer a diverse range of medical services, encompassing routine surgeries, emergency interventions, and specialized procedures across various medical specialties. The sheer volume and variety of surgical interventions conducted in hospitals create a substantial demand for anesthesia services, and inhalation anesthesia, with its ability to provide rapid induction and adjustable sedation levels, aligns seamlessly with the dynamic environment of hospital operating rooms. Additionally, hospitals provide a comprehensive infrastructure for anesthesia administration and patient care. They possess well-equipped operating suites, sophisticated monitoring systems, and experienced anesthesia teams capable of managing a wide spectrum of cases. This robust setup allows hospitals to efficiently manage the complexities associated with different surgeries, including those requiring inhalation anesthesia. Furthermore, the presence of specialized units within hospitals, such as pediatric and cardiac surgery departments, highlights the versatility of inhalation anesthesia across diverse patient populations and procedural requirements.
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
North America exhibits a clear dominance, accounting for the largest inhalation anesthesia market share
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada), Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others), Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others), Latin America (Brazil, Mexico, and others), and the Middle East and Africa. According to the report, North America accounted for the largest market share.
North America is characterized by its emphasis on medical advancements and innovation. The presence of renowned research institutions, academic medical centers, and cutting-edge pharmaceutical companies fosters an environment conducive to the development of new anesthetic agents, delivery methods, and monitoring technologies. This commitment to innovation not only enhances patient care but also attracts healthcare professionals to adopt state-of-the-art anesthesia practices, including inhalation anesthesia techniques. The region's regulatory landscape and adherence to stringent safety standards further contribute to its dominance. Regulatory agencies such as the U.S. Food and Drug Administration (FDA) play a pivotal role in ensuring the safety and efficacy of anesthesia agents and equipment. This rigorous oversight augments the confidence of healthcare providers and patients in the use of inhalation anesthesia, solidifying North America's position as a leader in the field. Also, North America's focus on medical education and training ensures that anesthesia providers are well-equipped to administer inhalation anesthesia safely and efficiently.
Pharmaceutical and medical device companies are heavily investing in research and development to create advanced anesthetic agents, delivery systems, and monitoring technologies. Moroever, companies are frequently introducing new inhalation anesthesia products and equipment to cater to the evolving needs of healthcare providers and patients. These products often incorporate the latest technological advancements, such as more precise vaporizers, integrated monitoring systems, and user-friendly interfaces. Additionally, leading players are focusing on developing innovative technologies that enhance the administration and monitoring of inhalation anesthesia. This includes the integration of electronic medical records (EMR) systems, real-time data analysis, and remote monitoring capabilities to ensure optimal patient care and safety. Additionally, numerous companies are providing training and educational programs to healthcare professionals, including anesthesiologists, nurse anaesthetists, and operating room staff. These programs help ensure that healthcare providers are well-versed in the latest techniques, technologies, and safety measures related to inhalation anesthesia.
Abbvie Inc.
Baxter International Inc.
Fresenius SE & Co. KGaA
Halocarbon Products Corporation
Hikma Pharmaceuticals PLC
Lunan Pharmaceutical Group Co. Ltd
Merck KGaA
Piramal Enterprises Ltd.
Troikaa Pharmaceuticals Ltd.
In May 2023, Piramal Enterprises Ltd collaborated with plus therapeutics to meet increase in investigational drug demand for ongoing and planned clinical trials.
In April 2023, Baxter International Inc. launched Zosyn Premix. It is indicated for the treatment of multiple infections caused by susceptible bacteria.
In December 2021, Hikma Pharmaceuticals PLC launched Bupivacaine HCl Injection. Bupivacaine HCl Injection is indicated in adults for the production of local or regional anesthesia or analgesia for surgery, dental and oral surgery procedures, diagnostic and therapeutic procedures, and for obstetrical procedures.